QQ客服 官方微博 反馈留言

	Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant tre
	Moreno-Aspitia, Alvaro; Holmes, Eileen McCormick; Jackisch, Christian; De Azambuja, Evandro; Boyle, Frances M.; Hillman, David W.; Korde, Larissa A.; Fumagalli, Debora; Izquierdo, Miguel A.; McCullough, Ann E.
	2017
会议名称	JOURNAL OF CLINICAL ONCOLOGY
会议日期	2017-05-20
收录类别	CPCI-S
URL标识	查看原文
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/6369600
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Moreno-Aspitia, Alvaro,Holmes, Eileen McCormick,Jackisch, Christian,et al. Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L) or their combination (L plus T) in the adjuvant tre[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2017-05-20.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。